ACASTI PHARMA INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.705 USD | +0.56% |
|
-1.99% | -6.40% |
| Feb. 12 | Acasti Pharma Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 | CI |
| Feb. 07 | Craig-Hallum Initiates Acasti Pharma With Buy Rating, $6 Price Target | MT |
Valuation
| Fiscal Period: Marzo | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 106.3 | 48.2 | 150.8 | 67.55 | 27.72 | 34.6 | - | - |
| Enterprise Value (EV) 1 | 106.3 | 48.2 | 150.8 | 67.55 | 27.72 | 34.6 | 34.6 | 34.6 |
| P/E ratio | - | -1.3 x | -3.58 x | -4.37 x | -0.5 x | -1.9 x | -2.45 x | -2.69 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | - | - | - | 28.6 x |
| EV / Revenue | - | - | - | - | - | - | - | 28.6 x |
| EV / EBITDA | -2.52 x | - | - | - | - | -1.83 x | -1.59 x | -1.34 x |
| EV / FCF | - | -1.51 x | - | - | - | -1.76 x | -1.59 x | -1.38 x |
| FCF Yield | - | -66.1% | - | - | - | -56.7% | -62.9% | -72.2% |
| Price to Book | 5.29 x | - | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 1,628 | 1,879 | 4,169 | 7,381 | 7,435 | 9,399 | - | - |
| Reference price 2 | 65.28 | 25.65 | 36.18 | 9.151 | 3.728 | 3.681 | 3.681 | 3.681 |
| Announcement Date | 6/26/19 | 6/29/20 | 6/22/21 | 6/21/22 | 6/23/23 | - | - | - |
1CAD in Million2CAD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: Marzo | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | 1.21 |
| EBITDA 1 | -42.19 | - | - | - | - | -18.95 | -21.77 | -25.8 |
| EBIT 1 | -45.02 | -30.56 | - | -20.25 | -24.56 | -16.26 | -23.52 | -25.8 |
| Operating Margin | - | - | - | - | - | - | - | -2,132.48% |
| Earnings before Tax (EBT) 1 | - | -34.94 | - | -13.6 | -68.44 | -19.62 | -23.52 | -25.8 |
| Net income 1 | - | -34.94 | -24.34 | -12.76 | -55.88 | -18.41 | -23.52 | -25.8 |
| Net margin | - | - | - | - | - | - | - | -2,132.48% |
| EPS 2 | - | -19.72 | -10.09 | -2.094 | -7.529 | -1.935 | -1.505 | -1.371 |
| Free Cash Flow 1 | - | -31.86 | - | - | - | -19.62 | -21.77 | -25 |
| FCF margin | - | - | - | - | - | - | - | -2,065.87% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 6/26/19 | 6/29/20 | 6/22/21 | 6/21/22 | 6/23/23 | - | - | - |
1CAD in Million2CAD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: March | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 | 2025 Q3 | 2025 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA 1 | - | - | - | - | - | - | - | -4.096 | -4.972 | -4.972 | -5.644 | -5.644 | -5.644 |
| EBIT 1 | - | -5.674 | -5.72 | -5.667 | -6.012 | -5.969 | -2.894 | -4.097 | -5.376 | -5.376 | -6.048 | -6.048 | -6.048 |
| Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | - | -4.792 | -5.914 | -5.558 | -49.99 | -5.778 | -5.144 | -3.499 | -5.376 | -5.376 | -6.048 | -6.048 | -6.048 |
| Net income 1 | 1.22 | -4.792 | -5.072 | -5.192 | -38.31 | -5.391 | -4.528 | -3.219 | -5.376 | -5.376 | -6.048 | -6.048 | -6.048 |
| Net margin | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EPS 2 | 0.2239 | -0.6879 | -0.3102 | -0.7216 | -5.151 | -0.7236 | -0.5948 | -0.2827 | -0.4700 | -0.3630 | -0.4170 | -0.4170 | -0.3230 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/10/21 | 2/14/22 | 6/21/22 | 2/14/23 | 6/23/23 | 8/11/23 | 11/13/23 | 2/12/24 | - | - | - | - | - |
1CAD in Million2CAD
Estimates
Balance Sheet Analysis
| Fiscal Period: March | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | - | -31.9 | - | - | - | -19.6 | -21.8 | -25 |
| ROE (net income / shareholders' equity) | -369% | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share | 12.30 | - | - | - | - | - | - | - |
| Cash Flow per Share | 12.60 | - | - | - | - | - | - | - |
| Capex | 0.7 | 0.44 | - | - | - | - | - | - |
| Capex / Sales | - | - | - | - | - | - | - | - |
| Announcement Date | 6/26/19 | 6/29/20 | 6/22/21 | 6/21/22 | 6/23/23 | - | - | - |
1CAD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
3.681
CAD
Average target price
8.063
CAD
Spread / Average Target
+119.02%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -6.40% | 25.28M | |
| +34.35% | 693B | |
| +29.39% | 584B | |
| -3.49% | 372B | |
| +20.15% | 332B | |
| +6.19% | 294B | |
| +14.11% | 239B | |
| -3.03% | 211B | |
| +10.02% | 210B | |
| +9.21% | 168B |
- Stock Market
- Equities
- ACST Stock
- Financials Acasti Pharma Inc.